trial · primary record
bendamustine hydrochloride
B-cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 92 |
| Primary completion | 2030-03 |
| Primary endpoint | Incidence of the following side effect occurring within 4 weeks (28 days) from the CAR-T infusion: Occurrence of grade ≥3 cytokine release syndrome (CRS) |
| Registry ID | NCT07593482 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:44.974Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07593482
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.